Highly active antiretroviral therapy and tuberculosis control in Africa: synergies and potential
Abstract HIV/AIDS (human immunodeficiency virus/acquired immunodeficiency syndrome) and TB (tuberculosis) are two of the world's major pandemics, the brunt of which falls on sub-Saharan Africa. Efforts aimed at controlling HIV/AIDS have largely focused on prevention, little attention having been paid to care. Work on TB control has concentrated on case detection and treatment. HIV infection has complicated the control of tuberculosis. There is unlikely to be a decline in the number of cases of TB unless additional strategies are developed to control both this disease and HIV simultaneously. Such strategies would include active case-finding in situations where TB transmission is high, the provision of a package of care for HIV-related illness, and the application of highly active antiretroviral therapy. The latter is likely to have the greatest impact, but for this therapy to become more accessible in Africa the drugs would have to be made available through international support and a programme structure would have to be developed for its administration. It could be delivered by means of a structure based on the five-point strategy called DOTS, which has been adopted for TB control. However, it may be unrealistic to give TB control programmes the responsibility for running such a programme. A better approach might be to deliver highly active antiretroviral therapy within a comprehensive HIV/AIDS management strategy complementing the preventive work already being undertaken by AIDS control programmes. TB programmes could contribute towards the development and implementation of this strategy.
Keywords HIV infections/drug therapy; Acquired immunodeficiency syndrome/drug therapy; Antiretroviral therapy, Highly active; Anti-HIV agents/administration and dosage; Antitubercular agents/administration and dosage; Drug costs; Delivery of health care, Integrated; Africa South of the Sahara (source: MeSH, NLM).
Mots clés HIV, Infection/chimiothérapie; SIDA/chimiothérapie; Thérapie antirétrovirale hautement active; Agents anti-VIH/administration et posologie; Antituberculeux/ administration et posologie; Coût médicaments; Distribution intégrée soins; Afrique subsaharienne (source: MeSH, INSERM).
Palabras clave Infecciones por VIH/quimioterapia; Síndrome de inmunodeficiencia adquirida/quimioterapia; Terapia antirretroviral altamente activa; Agentes anti VIH/administración y dosificación; Agentes antituberculosos/administración y dosificación; Costos en drogas; Entrega integrada de atención de salud; África del Sur del Sáhara (fuente: DeCS, BIREME).
Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) is the modern world's principal pandemic. It has claimed 22 million lives and created 13 million orphans (1). Sub-Saharan Africa bears the brunt of the catastrophe. In this region with less than 10% of the world's population there are 25.3 million people with HIV/AIDS, i.e. 70% of all cases globally. In 2000 there were 3.8 million new HIV infections in sub-Saharan Africa and 2.4 million people with HIV/AIDS died, representing 80% of all deaths attributable to AIDS.
AIDS kills young adults in their most productive years, depriving the region of the skills and knowledge that are essential for economic development. Because of AIDS, large numbers of children have to be brought up by their grandparents. Many orphans cannot attend school, suffer from poverty and malnutrition, and are drawn into crime, violence, and commercial sex. AIDS retards development and may create conditions conducive to political instability.
In 1999 there were estimated to be 8.4 million new cases of TB in the world (2). Sub-Saharan Africa is the region most severely affected by this disease (3). HIV fuels the tuberculosis (TB) epidemic: nearly three-quarters of people infected with both HIV and Mycobaterium tuberculosis live in sub-Saharan Africa (3). WHO predicts that by 2005 there will be 3.4 million TB cases in Africa (2).
Efforts to control HIV/AIDS and TB in sub-Saharan Africa
HIV/AIDS control efforts
Control efforts have largely centred on prevention. Strategies for reducing the sexual transmission of HIV have focused on condom usage, treating sexually transmitted infections, and reducing unsafe sexual behaviour. In hospitals, donated blood is screened for HIV, reducing but not eliminating the risk of transmitting HIV during transfusions (4).
Voluntary counselling and HIV testing have been advocated as a golden opportunity for educating and bringing about behavioural change. However, nearly 90% of infected people in Africa do not know their HIV serostatus (5). Among the many reasons for this are a general shortage of accessible voluntary counselling and HIV testing services, counselling of poor quality, poor uptake of voluntary counselling and HIV testing, and denial of the HIV/AIDS problem by both individuals and communities. Until now there has been a lack of understanding among policy-makers and health care providers that voluntary counselling and HIV testing and prevention should be linked to care. For the majority of people with HIV-related disease in Africa, only poor-quality clinical care and inadequate resources are available for treating serious opportunistic infections and tumours, e.g. Kaposi's sarcoma. There is almost no routine use of prophylaxis against opportunistic infections and virtually no access to antiretroviral drugs. Thus there is little incentive for people to ask for their HIV serostatus to be determined.
The aspect of care most likely to benefit an individual with HIV/AIDS is highly active antiretroviral therapy (HAART). Furthermore, there is evidence that lowering the viral load with HAART may reduce the likelihood of transmitting HIV to others (6). In industrialized countries, HAART has dramatically improved the survival of patients living with HIV/AIDS. Indeed, it has transformed AIDS from a fatal disease into a potentially treatable and chronic condition. HAART is the standard care for all patients with HIV-related disease in these countries. In contrast, only some 25 000 of Africa's 25 million HIV-positive individuals receive antiretroviral therapy of any kind. Many of these patients receive the drugs in a chaotic and unregulated manner in the private sector, with grave implications for the rapid development of drug resistance (7). The main reasons given for lack of availability of this therapy have been the high cost of the drugs and the perceived inability of the health infrastructure in Africa to manage the complexities of HAART.
TB control efforts
Control efforts have centred on case detection and treatment. The strategy is simple. Standardized combination chemotherapy is provided at least to all patients with smear-positive pulmonary TB. This treatment cures the disease and aims to prevent further transmission of infection. The targets for control include curing 85% of detected new smear-positive cases of pulmonary TB and detecting 70% of existing cases (8).
The success of this strategy depends on the implementation of a control policy known as DOTS. DOTS is a five-point package (Box 1) associated with various key operations (9). Despite the poor health infrastructure in Africa, 55% of the population is covered by DOTS, 60% of TB cases notified are treated under a DOTS programme, and 63% of such cases successfully complete treatment. However, the implementation of a good DOTS programme is not easy and requires adequate funding and human resources (10).
Negative effects of HIV on TB control efforts
HIV infection of TB patients adds to the difficulties encountered in programmes trying to implement the DOTS strategy (Box 2). The large increase in the number of cases of TB during the last 15 years has created a need for more staff, drugs, and resources. Where patients are hospitalized for the initial phase of treatment, TB wards have become overcrowded. This has forced the decentralization of treatment to peripheral health centres and the community. Decentralization, although patient-friendly, complicates the logistics of observing drug administration and maintaining the security of anti-TB drugs (especially of rifampicin, which is known by communities to be a useful drug for treating cough, diarrhoea, and sexually transmitted infections). The supervision and monitoring of TB control activities also becomes more difficult and demanding with a decentralized approach. HIV- positive TB patients experience many HIV-related illnesses during treatment. They also experience an increased frequency of adverse drug reactions leading to interruptions of treatment and occasional fatalities (11). Mortality rates have risen: 20 - 30% of HIV-positive smear-positive pulmonary TB patients die before the end of treatment (11). Even higher mortality rates are observed in patients with smear-negative TB (12). Recurrence rates of TB have increased (11), adding to the large number of new patients presenting annually for treatment. Health care workers also experience considerable morbidity and mortality attributable to AIDS, and this in turn compromises the quality of health care delivery.
African countries with good DOTS programmes continue to have escalating notifications of TB cases in the face of high HIV infection rates (13). DOTS alone may not be sufficient to control TB in areas of epidemic HIV infection: additional strategies may be needed (14).
Interventions to control TB and HIV
Various additional interventions may help to control TB and HIV concomitantly (Box 3). Where TB transmission is likely to be high, e.g. in prisons, boarding schools, health care institutions and households of diagnosed TB patients, active rather than passive case-finding may be better for rapid case detection. Access to specific interventions targeted at HIV-related diseases requires knowledge of the individual's HIV serostatus. This is best achieved through voluntary counselling and HIV testing sites, which can either be free-standing and providing a service to the general population or integrated into the general health care service and providing a service to the sick. Same-day HIV testing, especially by means of rapid whole-blood finger-prick kits, facilitates voluntary counselling and HIV testing and allows quick referral to other support services. A package of care is required which includes a two-way referral system between health facilities and the community. This package involves psychosocial support, screening for sexually transmitted infections and TB, clinical care for opportunistic infections, palliative care for terminal illness, prevention of mother-to-child transmission of HIV, home-based care, preventive therapy, and the possibility of using antiretroviral drugs.
In Africa, preventive therapy for HIV-related infections in general and for HIV-related TB is currently based on cotrimoxazole and isoniazid, respectively. In Côte d'Ivoire, cotrimoxazole significantly reduced the case-fatality rate in HIV-positive TB patients (15) and reduced morbidity in HIV- infected patients without TB (16). The Joint United Nations Programme on HIV/AIDS has therefore provisionally recommended that cotrimoxazole be given to all patients in Africa living with AIDS, which, by definition, includes HIV-positive patients with TB (17). However, it would be prudent to gather more evidence about the efficacy of this intervention because of different patterns of disease and differing drug-resistance profiles in other parts of the region. Even if cotrimoxazole is effective, its widespread use by AIDS patients may have serious adverse consequences for the treatment of malaria in countries where sulphadoxine-pyrimethamine is used (18).
The efficacy of primary preventive treatment with isoniazid to reduce the incidence of TB in HIV-positive persons, at least in the short to medium term, has been demonstrated in placebo-controlled studies (19). Secondary isoniazid preventive therapy in HIV-positive patients who had completed rifampicin-containing anti-TB treatment significantly reduced the risk of recurrent TB in a small study in Haiti (20). Although there are doubts about the value of isoniazid preventive therapy as a TB control strategy, it deserves to be included as part of the package of care offered to HIV-positive individuals.
The greatest improvement in the quality of life and the largest reduction in death rates among HIV-positive patients, whether or not they have TB, is likely to be achieved by HAART. If HAART is to become more available to people in Africa the drugs have to be made accessible and an infrastructure has to be created in order to ensure that they can be administered in a structured, safe and secure way.
Access to antiretroviral drugs
Pharmaceutical companies have significantly reduced the cost of antiretrovirals, and drug companies in Brazil, India, and Thailand are producing cheap generic versions (21). However, for very poor countries spending less than US$ 5 per capita per year on health, antiretroviral drugs are still too expensive unless there is additional assistance.
A meaningful challenge to the AIDS epidemic requires a huge increase in donor support, not only for antiretrovirals but also for basic prevention and care packages (22). During 1996 - 98, official development assistance for HIV/AIDS in sub-Saharan Africa was approximately US$ 130 million per year, a funding level totally incommensurate with the severity of the AIDS epidemic. A strong case has been made for a global annual budget of US$ 7.5 billion in the form of grants in order to support HAART and palliative treatment (22).
In July 2001 the Global Fund to Fight AIDS, Tuberculosis and Malaria was established in order to support research into these conditions and their prevention and treatment (23). The United Nations has calculated that up to US$ 10 billion are needed annually to fight AIDS alone.
Administration of antiretroviral drugs
Antiretroviral drugs must be provided within a structured framework. The structure used to deliver and monitor anti-TB treatment to TB patients throughout the developing world could be a model for delivering antiretroviral therapy (24). The overall objective would be to reduce mortality, morbidity, and the transmission of HIV. Standardized combination antiretroviral therapy would be used for HIV-positive patients with symptoms. Targets for antiretroviral therapy would have to be developed: they might include lifelong treatment and high drug-adherence rates to minimize the development of drug resistance. There would be an antiretroviral policy package, with five key elements (Box 4), similar to that adopted for TB control. An important aspect of proper case management is the supervised administration of tablets, i.e. directly observed therapy, in order to ensure that patients adhere to the regimen. This is vital if individual benefit is to be maximized and drug resistance is to be forestalled. In an impoverished community in rural Haiti, directly observed HAART was effective as part of a package of care for a small number of patients with AIDS (25). This supported the view that HAART could be delivered within the setting of a minimum health infrastructure.
Such a programme could not be implemented countrywide all at once. A phased approach would be necessary. A preparatory phase would establish the infrastructure necessary for the administration of HAART. This might include: management and coordination structures; HIV/AIDS clinics and laboratory support facilities; recording, reporting, and training materials; systems for drug procurement, distribution, and security; and plans for supervision.
In the second phase, there would be rigorous piloting of the chosen triple combination therapy. Intensive clinical and laboratory monitoring would ensure that the regimen was safe and well tolerated. The aim would be to define simple and robust clinical management algorithms for the monitoring of treatment and complications, because, in most districts of Africa, laboratory monitoring using CD4+-lymphocyte counts and the determination of viral load would not be feasible. While this phase was taking place, the third phase, involving feasibility assessment, would begin. Earmarked districts would be strengthening their infrastructure so as to provide a package of care for people living with AIDS. The introduction of HAART would be conditional on this package of care being in place and operational. Once districts were ready the feasibility of managing HIV/AIDS patients using HAART would have to be tested. If the feasibility studies were successful the programme could be expanded to become countrywide.
Should antiretroviral therapy be delivered to AIDS patients through national TB control programmes?
The proposed programme for delivering HAART is based on a framework similar to that for TB control. Building on an established TB control infrastructure would be cost-effective. National TB control programmes have experience of providing, monitoring, and supervising the care of patients for long periods of time and are in a position to develop and implement a structure within which HAART can be effectively and safely administered.
As HIV is the main factor responsible for the current epidemic of TB in Africa, an integrated programme has a greater chance of affecting the TB burden here than any course of action undertaken by TB control programmes alone. TB is the main opportunistic infection resulting from HIV: consequently, many patients would have both conditions. Adverse drug effects occurring when patients are on both anti-TB treatment and HAART are best managed in a single programme. Directly observed therapy in respect of anti-TB treatment and HAART can be administered by the same provider. In each country a joint approach would provide a real focus for collaboration between the national TB programme and the national AIDS programme.
In a country with a well-established HIV/AIDS epidemic, the demand for antiretroviral drugs would probably be enormous and the large additional number of patients would threaten to overwhelm the services of the TB programme, even if extra staff and resources were allocated. HIV-positive patients without TB might be at risk of acquiring TB when undergoing HAART if they had to join outpatient queues in which there were both TB patients and suspected cases. Anti-TB treatment continues for six to eight months, whereas HAART is lifelong. An antiretroviral programme requires more demanding logistics. Although rifampicin has a well-known street-market value for the treatment of conditions other than TB, antiretroviral drugs can be expected to have an enormous national and international street value, and rigorous systems of monitoring drug use would have to be developed in order to safeguard the drugs from theft and prevent abuse.
One way forward is to use the DOTS model and integrate the delivery of HAART into a comprehensive HIV/AIDS management strategy to complement prevention efforts already undertaken by AIDS control programmes. The key entry point to comprehensive HIV/AIDS management would be voluntary counselling and HIV testing. HIV-positive patients without TB would receive HAART and have their treatment monitored at AIDS clinics. If adequate human resources were available, HIV-positive patients with TB could be treated by national TB programmes, which could also take responsibility for the management of antiretroviral therapy during the course of anti-TB treatment. This would obviate the need for TB patients having to visit different units in order to obtain anti-TB drugs and HAART. Because rifampicin interacts with protease inhibitors and non-nucleoside reverse transcriptase inhibitors (26), special attention would have to be paid to the antiretroviral regimen during anti-TB treatment. It would be necessary to train the staff on TB programmes to manage the most appropriate antiretroviral regimens for the initial and continuation phase of anti-TB treatment. Once anti- TB treatment had been completed the patient could return to the main antiretroviral drug monitoring system.
In any of these approaches there might be reluctance by donors to support what appeared to be another vertical disease programme at a time when thinking on health delivery in Africa hinges on health sector reform. It would be essential for staff on AIDS and TB control programmes to work closely with health planners in order to ensure that core activities such as regular drug supplies, supervision, monitoring, and recording were maintained and that they continued uninterruptedly.
Whether HAART becomes part of the package of care for HIV-positive patients in sub-Saharan Africa depends on the support and commitment of the international community, because countries with very limited resources would be unable to support an antiretroviral programme, notwithstanding large reductions in drug costs. Also critical is the success or otherwise of phased studies on effectiveness and feasibility. The challenges are considerable, but given the scale of the epidemic, the first steps should be taken as soon as possible.
Conflicts of interest: none declared.
Traitement antirétroviral et lutte antituberculeuse en Afrique : synergies et potentiel
Le VIH/SIDA (virus de l'immunodéficience humaine/syndrome d'immunodéficience acquise) et la tuberculose figurent parmi les grandes pandémies qui sévissent à l'échelle mondiale, particulièrement en Afrique subsaharienne. Les efforts de lutte contre le VIH/SIDA ont été largement axés sur la prévention et ont peu porté sur les soins. Les travaux sur la lutte antituberculeuse se sont quant à eux concentrés sur la détection et le traitement des cas. L'infection par le VIH complique la lutte contre la tuberculose. Il est peu probable que l'on puisse assister à un déclin du nombre de cas de tuberculose tant qu'on n'aura pas élaboré de nouvelles stratégies pour lutter simultanément contre cette maladie et contre le VIH. Ces stratégies devront comporter un dépistage actif des cas là où la transmission de la tuberculose est intense, la fourniture d'un ensemble de soins pour les maladies associées au VIH et l'application d'un traitement antirétroviral efficace. C'est ce dernier élément qui devrait avoir le maximum d'impact, mais pour le rendre plus accessible en Afrique, il faudra mettre les médicaments à disposition par le biais d'un soutien international et mettre en place une structure programmatique en vue de leur administration. Le traitement pourrait être dispensé selon une stratégie en cinq points appelée DOTS adoptée pour la lutte antituberculeuse. Cependant, il n'est peut-être pas réaliste de charger les programmes de lutte antituberculeuse de ce surcroît de responsabilité. Une meilleure approche pourrait consister à délivrer un traitement antirétroviral efficace dans le cadre d'une stratégie globale de prise en charge du VIH/SIDA, en complément du travail de prévention déjà réalisé par les programmes de lutte contre le SIDA. Les programmes de lutte antituberculeuse pourraient contribuer au développement et à la mise en œuvre de cette stratégie.
Terapia antirretroviral de gran potencia y lucha contra la tuberculosis en África: sinergias y posibilidades
La infección por el VIH/SIDA (virus de la inmunodeficiencia humana/síndrome de inmunodeficiencia adquirida) y la tuberculosis son dos de las pandemias más graves del mundo, y castigan en especial al África subsahariana. Los esfuerzos encaminados a combatir el VIH/SIDA se han centrado en gran parte en la prevención, habiéndose prestado poca atención a la asistencia, y las actividades de control de la tuberculosis se han centrado en la detección y el tratamiento de los casos. La infección por el VIH ha complicado el control de la tuberculosis. Es improbable que se produzca una disminución del número de casos de tuberculosis a menos que se desarrollen otras estrategias para controlar simultáneamente esta enfermedad y el VIH. Esas estrategias incluirían la búsqueda activa de casos en las situaciones de alta transmisión de la tuberculosis, el suministro de un paquete asistencial para las enfermedades relacionadas con el VIH, y la aplicación de terapia antirretroviral de gran potencia. Esto último es lo que más impacto podría tener, pero para ampliar el acceso a ese tratamiento en África los medicamentos se deberían ofrecer con ayuda internacional, y habría que desarrollar una estructura de programa para su administración. Podría establecerse una estructura basada en la estrategia en cinco puntos DOTS adoptada para combatir la tuberculosis. Sin embargo, la pretensión de delegar en los programas de control de la tuberculosis la responsabilidad de ejecutar un programa de esa naturaleza es quizá poco realista. Una alternativa preferible consistiría tal vez en el suministro de terapia antirretroviral de gran potencia en el marco de una estrategia integral de manejo de la infección por el VIH/SIDA que complementase las actividades preventivas ya emprendidas por los programas de control del SIDA. Los programas contra la tuberculosis podrían contribuir al desarrollo y aplicación de esa estrategia.
1. AIDS epidemic update: December 2000. Geneva: Joint United Nations Programme on HIV/AIDS; 2000. Unpublished document UNAIDS/00.44E; WHO/CDS/CSR/EDC/2000.9.
2. Global tuberculosis control. Geneva: World Health Organization; 2001. Unpublished document WHO/CDS/TB/2001.287.
3. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282:677-86.
4. Moore A, Herrera G , Nyamongo J, Lackritz E, Granade T, Nahlen B, et al. Estimated risk of HIV transmission by blood transfusion in Kenya. Lancet 2001;358:657-60.
5. AIDS epidemic update: December 1998. Geneva: Joint United Nations Programme on HIV/AIDS; 1998. Unpublished document UNAIDS/98.35; WHO/ EMC/VIR/98.4; WHO/ASD/98.3.
6. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Chuanjun L, Wabwire- Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. New England Journal of Medicine 2000;342:921-9.
7. Horton R. African AIDS beyond Mbeki: tripping into anarchy. Lancet 2000;356:1541-2.
8. Maher D, Chaulet P, Spinaci S, Harries AD for the Global Tuberculosis Programme. Treatment of tuberculosis: guidelines for national programmes. 2nd ed. Geneva: World Health Organization; 1997. Unpublished document WHO/TB/97.220.
9. WHO Tuberculosis Programme. Framework for effective tuberculosis control. Geneva: World Health Organization; 1994. Unpublished document WHO/ TB/94.179.
10. Volmink J, Matchaba P, Garner P. Directly observed therapy and treatment adherence. Lancet 2000;355:1345-50.
11. Raviglione MC, Harries AD , Msiska R, Wilkinson D, Nunn P. Tuberculosis and HIV: current status in Africa. AIDS 1997;11 Suppl B: S115-23.
12. Harries AD, Nyangulu DS, Kang'ombe C, Ndalama D, Glynn JR, Banda H, et al. Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba hospital, Malawi. Transactions of the Royal Society of Tropical Medicine and Hygiene 1998; 92:343-7.
13. Kenyon TA, Mwasekaga MJ, Huebner R, Rumisha D, Binkin N, Maganu E. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. International Journal of Tuberculosis and Lung Disease 1999;3:4-11.
14. de Cock KM, Chaisson RE. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. International Journal of Tuberculosis and Lung Disease 1999;3:457-65.
15. Wiktor SZ, Sassan-Morroko M, Grant AD, Abouya L, Karon JM, Maurice C, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1 infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Lancet 1999;353:1469-75.
16. Anglaret X, Chene G, Attia A, Toure S, Lafont S, Combe P, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 1999;353:1463-8.
17. Provisional WHO/UNAIDS secretariat recommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/ AIDS in Africa. Geneva: Joint United Nations Programme on HIV/AIDS; 2000.
18. Iyer JK, Milhous, WK Cortese, JF Kublin JG, Plowe CV. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet 2001; 358:1066-7.
19. Wilkinson D, Squire SB, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. BMJ 1998;317:625-9.
20. Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson WD, Pape JW. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV- 1-infected individuals: a randomised trial. Lancet 2000;356:1470-4.
21. Kumar S. Indian company offers low cost AIDS drugs. Lancet 2001; 357:616.
22. Attaran A, Sachs J. Defining and refining international donor support for combating the AIDS epidemic. Lancet 2001;357:57-61.
23. Brugha R, Walt G. A global health fund: a leap of faith? BMJ 2001;323: 152-4.
24. Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwa O, Salaniponi FML. Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 2001; 358:410-4.
25. Farmer P, Leandre F, Mukherjee JS, Claude MS, Nevil P, Smith-Fawzi MC, et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet 2001;358:404-9.
26. Pozniak AL, Miller R, Ormerod LP. The treatment of tuberculosis in HIV-infected persons. AIDS 1999;13:435-45.
1 Technical Adviser, National Tuberculosis Control Programme, Ministry of Health, Lilongwe, Malawi. Correspondence should be addressed to this author, c/o British High Commission, PO Box 30042, Lilongwe 3, Malawi (email: firstname.lastname@example.org).
2 Coordinator, PROTEST Project, National Tuberculosis Control Programme, Lilongwe, Malawi; and Lecturer in Tropical Medicine, Liverpool School of Tropical Medicine, Liverpool, England.
3 Coordinator, PROTEST Project, National Tuberculosis Control Programme, Lilongwe, Malawi.
4 Programme Manager, National Tuberculosis Control Programme, Ministry of Health, Lilongwe, Malawi.
Ref. No. 01-1638